Skip to main content

Table 1 Licensed prolonged-release opioid agonist therapy products at 31st December 2018

From: Prolonged-release opioid agonist therapy: qualitative study exploring patients’ views of 1-week, 1-month, and 6-month buprenorphine formulations

Pharmaceutical drug Delivery system Duration Brand name Company Countries where licensed (year of approval)
Buprenorphine Depot injection 1 month Sublocade™ Indivior, Richmond, VA, USA USA (2017)
Buprenorphine Depot injection 1 week and 1 month Buvidal®/
Camurus AB, Lund, Sweden Europe (2018) and Australia (2018)
Buprenorphine Implant 6 months Probuphine® Titan Pharmaceuticals, Inc., San Francisco, CA, USA USA (2016)